Plaque psoriasis with renal dysfunction successfully treated with ixekizumab.

Area of Science:

• Immunodermatology
• Nephrology
• Pharmacology

Background:

• Psoriasis is a chronic inflammatory skin condition often co-occurring with chronic kidney disease.
• Ixekizumab, a monoclonal antibody, treats moderate-to-severe plaque psoriasis.
• The safety and efficacy of ixekizumab in patients with renal insufficiency remain uninvestigated.

Observation:

• Two cases of plaque psoriasis patients with varying degrees of renal dysfunction were treated with ixekizumab.
• Treatment involved standard dosing without any dose reduction.
• Patients were monitored for adverse events and changes in renal function.

Findings:

• Ixekizumab demonstrated successful treatment of plaque psoriasis in both patients.
• No adverse side effects were reported during the treatment period.
• No evidence of further kidney injury or deterioration in renal function was observed.

Implications:

• Ixekizumab may be a safe and effective treatment option for plaque psoriasis patients with renal dysfunction.
• Further clinical studies are warranted to confirm these findings in a larger population.
• This could expand treatment options for psoriasis patients with common comorbidities.